Clinical Research Directory

Inclusion Criteria Stage 1: * Have given written informed consent to participate in stage 1 * Be aged 16 years or over at the time of signing the informed consent form * Presence of a hypodense pancreatic mass on contrast enhanced CT scan highly suspicious of operable primary pancreatic cancer as assessed by a pancreatic multi-disciplinary team (MDT) * Have not had pre-operative systemic therapy or radiotherapy Inclusion Criteria Stage 2: * Have participated in stage 1 of the study * Have confirmed histological or cytological diagnosis of primary pancreatic adenocarcinoma OR radiological evidence of pancreatic head mass with supportive cytological or histological findings. * Be scheduled to undergo pancreatico-duodenectomy (Whipple's) resection. * Written informed consent to participate in stage 2 * Aged 16 years or over at the time of signing informed consent * Have not had pre-operative systemic therapy or radiotherapy * ECOG Performance status 0-1 * Adequate renal function: GFR ≥ 60 Exclusion Criteria: * Any condition or abnormalities that in the judgement of the investigator/surgeon/clinical oncologist would place the patient at undue risk * Women who are known to be pregnant * Previous abdominal radiotherapy * Women of child-bearing potential who are unwilling to use 2 highly effective forms of contraception during the study treatment period